ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA)

Historical Holders from Q1 2014 to Q3 2025

Symbol
ENTA on Nasdaq
CUSIP
29251M106
Type / Class
Equity / Common Stock, par value $0.01 per share
Shares outstanding
27.8M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
19M
Holdings value
$227M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
117
Number of buys
55
Number of sells
-51
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12.1% $41.8M 3.49M JANUS HENDERSON GROUP PLC Oct 31, 2025
Farallon Capital Partners, L.P. 9.9% $9.78M 2.11M Dapice Joshua J. Dec 31, 2024
Luly Jay R. 7.7% $7.9M 1.7M Jay R. Luly, Ph.D. Feb 12, 2025
BlackRock, Inc. 7.8% $7.76M 1.67M BlackRock, Inc. Mar 31, 2025
Deep Track Capital, LP 5.33% $17.8M 1.48M Deep Track Capital, LP Oct 2, 2025
INTEGRATED CORE STRATEGIES (US) LLC 4.1% -34.3% $13.6M -$2.92M 1.14M -17.6% Millennium Management LLC Sep 30, 2025

Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 19M $227M +$9.08M $11.97 117
2025 Q2 18.4M $139M -$1.13M $7.56 104
2025 Q1 18.6M $103M -$7.31M $5.52 108
2024 Q4 19.9M $114M -$17.5M $5.75 105
2024 Q3 21.2M $220M -$10.7M $10.36 109
2024 Q2 22.1M $287M -$4.64M $12.97 99
2024 Q1 22.4M $391M +$30.1M $17.46 105
2023 Q4 174K $1.64M +$52.7K $9.41 3
2023 Q3 20M $224M -$5.48M $11.17 128
2023 Q2 19.7M $421M -$18M $21.40 126
2023 Q1 19.7M $798M +$23.7M $40.44 141
2022 Q4 19.1M $890M -$45.1M $46.52 143
2022 Q3 19.6M $1.02B -$25.6M $51.87 151
2022 Q2 20.2M $953M +$14.8M $47.27 148
2022 Q1 19.5M $1.39B +$57.8M $71.18 160
2021 Q4 18.8M $1.4B -$51.5M $74.78 170
2021 Q3 19.4M $1.1B +$34.2M $56.81 139
2021 Q2 18.8M $828M -$26.9M $44.01 147
2021 Q1 19.4M $956M +$8.03M $49.32 144
2020 Q4 19.2M $809M +$16.5M $42.10 146
2020 Q3 18.8M $859M +$27.2M $45.78 166
2020 Q2 18.2M $915M +$18.1M $50.21 170
2020 Q1 18M $927M -$30.9M $51.43 149
2019 Q4 18.4M $1.14B +$22M $61.78 164
2019 Q3 17.9M $1.07B +$8.9M $60.08 167
2019 Q2 17.6M $1.49B +$13.1M $84.38 190
2019 Q1 17.8M $1.7B +$94.8M $95.52 193
2018 Q4 16.8M $1.19B +$6.54M $70.83 178
2018 Q3 16.6M $1.42B +$117M $85.46 191
2018 Q2 15.1M $1.75B +$46.1M $115.90 184
2018 Q1 14.7M $1.19B +$59M $80.91 175
2017 Q4 14M $822M +$75.2M $58.68 139
2017 Q3 12.8M $597M +$18.4M $46.80 119
2017 Q2 12.6M $454M -$5.67M $35.98 117
2017 Q1 12.8M $396M +$44.3M $30.80 122
2016 Q4 13.3M $444M +$17.8M $33.50 144
2016 Q3 13.1M $349M +$1.17M $26.61 133
2016 Q2 13.4M $296M -$1.42M $22.05 125
2016 Q1 14.2M $418M -$10.1M $29.37 149
2015 Q4 14.6M $483M -$21.9M $33.02 132
2015 Q3 14.5M $525M +$40.3M $36.14 136
2015 Q2 13.7M $615M +$77.8M $44.99 127
2015 Q1 12.3M $376M +$45.3M $30.62 113
2014 Q4 10.4M $530M +$30.3M $50.85 119
2014 Q3 9.99M $395M +$64.4M $39.57 109
2014 Q2 8.11M $349M +$52.8M $43.07 94
2014 Q1 8.43M $337M +$158M $39.99 77